Please assess the completion status of the following clinical trial:

Trial Title: Determining the Prognostic Value of Continuous Intrathecal Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous lumbar or thoracic spine surgery or lower thoracic/lumbar vertebral compression fracture~* Intractable pain of trunk (more than limbs)~* Patient who passed psychological evaluations as part of the usual clinical care prior to consideration of IDDS and are stable with current pain condition and medications~* Failed more conservative management.~Exclusion Criteria:~* Untreated coagulopathy or infection.~* Immune compromised state precluding having an implant.~* Allergic reactions to bupivacaine or fentanyl.~* Pregnancy~* Patients using more than 30 mg oral equivalents of morphine daily or who are unable to wean down below that dosage for more than 4 weeks before the prognostic intrathecal infusion test.~* Neurological deficits characterized as weakness in lower extremities with evidence of nerve damage~* Patients with cognitive disorders who would not be able to provide meaningful outcome responses

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Solution followed by Inactive Placebo Solution (Type: ACTIVE_COMPARATOR): Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml~6 hour washout followed by~Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
- Inactive Placebo Solution followed by Active Solution (Type: PLACEBO_COMPARATOR): Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline~6 hour washout followed by~Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).